Newcomer Nuvectra Ready To Compete In Spinal Cord Stim Market
This article was originally published in Clinica
The $1.6bn global spinal cord stimulation device market will welcome a new entrant next week after component manufacturer Greatbatch Inc. completes the spin-off of its neuromodulation subsidiary QiG Group LLC on March 14. The new company, named Nuvectra Corp., plans to formally launch its Algovita Spinal Cord Stimulation System into the US market in Q2 2016.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.